NEWS & ARCHIVE

New: Capital market prospectus 2022

For an investment in a share in the Private Limited Company (GmbH) of the issuer to be newly issued and held in trust and/or in a new atypical silent partnership with the issuer, to be entered into in trust, investors can obtain subscription forms online on the platform www.join-zytoprotec.at. In both investments the minimum subscription is 5,000 EUR. The subscription volume of both investment will amount to less than 5 mio. EUR. The offer period starts on 17th of October 2022 and will end with the expiry of 16th of October 2023. Click here to find our 2022 capital market prospectus (only german). 

Zytoprotec Phase II Peritoneal Dialysis Study: Last Patient Out

Vienna, Europe, November 14, 2016 – Zytoprotec, a biopharmaceutical company developing innovative dialysis fluids with cytoprotective properties, announced today that the last patient has completed treatment in a Phase II study with its lead product, PDprotec^®. The Company expects results of this trial to be available in the first quarter of 2017.

> read more

Zytoprotec's Novel Dialysis Product Meets Both Endpoints in Phase II Study

Vienna, Europe, June 9, 2017 – Zytoprotec, a biopharmaceutical company developing innovative dialysis fluids, announced today the highly promising outcome of the Phase II study of its peritoneal dialysis fluid PDprotec^®. In this double-blind, placebo-controlled cross-over study, the two primary endpoints were successfully met.

> read more

FDA Grants Orphan Drug Designation to Zytoprotec's Novel Dialysis Fluid

Vienna, Europe, December 14, 2017 – Zytoprotec, a biopharmaceutical company developing innovative dialysis fluids, announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to PDprotec^®, the Company's peritoneal dialysis fluid for the treatment of patients with end-stage renal disease (kidney failure).

> read more

Neue Therapieansätze für eine Verbesserung der Bauchfelldialyse

Christian Doppler Labor „Molekulare Stressforschung in der Peritonealdialyse“ an der MedUni Wien eröffnet – Förderung durch Wissenschafts-, Forschungs- und Wirtschaftsministerium

> read more

Zytoprotec geht mit neuer Geschäftsführung in Entwicklungs-Endspurt

Zwei Industrie-Veteranen mit erfolgreichen Karrieren in Biotech-Finanzierung und Medizinprodukte-Vertrieb gewonnen.

> read more